We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.28 | -0.78% | 35.80 | 452,217 | 16:54:09 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 35.82 | 35.87 | 36.05 | 35.79 | 36.05 | |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:54:10 | 54 | 35.82 | USD |
| Date | Time | Source | Headline |
|---|---|---|---|
| 16/1/2024 | 06:49 | DJN | Roche's Cancer Injection Tecentriq SC Gets European Commission Approval |
| 10/1/2024 | 13:45 | IHNW | GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons |
| 29/12/2023 | 22:07 | DJN | LumiraDx Agrees to Sell Point-of-Care Tech Platform to Roche |
| 19/12/2023 | 15:27 | DJN | Roche's Xolair Granted FDA Priority Review |
| 11/12/2023 | 15:31 | DJN | Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer.. |
| 08/12/2023 | 17:56 | DJN | Roche Obtains Positive Data on Early-Stage Breast Cancer Treatment |
| 08/12/2023 | 17:38 | DJN | Roche's Inavolisib Breast Cancer Drug Gets Positive Results |
| 06/12/2023 | 10:14 | DJN | Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials |
| 05/12/2023 | 06:54 | DJN | Roche's Inavolisib Breast Cancer Drug Shows Promise in Late-Stage Study |
| 04/12/2023 | 15:12 | DJN | Trending: Roche to Buy Carmot Therapeutics in Deal Worth Up to $3.1 Billion |
Roche (QX) (RHHBY) Charts1 Year Roche (QX) Chart |
|
1 Month Roche (QX) Chart |
Intraday Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
